25 October 2017 – Walder Wyss advises Abingworth and 5AM Venture on Nouscom’s Series B financing round. Nouscom is active in the development of tumor specific oncolytic viruses and patient specific cancer vaccines. The financing round was subscribed by Abingworth and 5AM Venture as well as by existing shareholders.

The Walder Wyss teams consists of Alexander Gutmans (Partner, Corporate, Venture Capital) and Jessica Aeschbach Flórez (Associate, Corporate).